



Request for Prior Authorization
SELECTED BRAND NAME DRUGS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Form with fields for IA Medicaid Member ID #, Patient name, DOB, Patient address, Provider NPI, Prescriber name, Phone, Prescriber address, Fax, Pharmacy name, Address, Phone, Pharmacy NPI, Pharmacy fax, NDC.

Prior authorization is required for selected brand-name drugs, as determined by the Department, for which there is available an "A" rated bioequivalent generic product as determined by the Federal Food and Drug Administration, unless the brand drug has been designated by the Department as preferred (payable) under the Iowa Medicaid Preferred Drug List (PDL).

- 1. Documentation of trials and therapy failures with two different generic manufacturers of the same chemical entity.
2. Documentation of the failure must include the specific adverse reaction as defined by the FDA (See Section B of the MedWatch form).

Trials may be overridden when evidence is provided that use of the generic product would be medically contraindicated.

Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_

Dosage Instructions: \_\_\_\_\_ Quantity: \_\_\_\_\_ Days Supply: \_\_\_\_\_

Diagnosis: \_\_\_\_\_

Previous therapy (include drug name(s), manufacturer/labeler, strength, exact date ranges, and specific failure reason):\* To be documented on MedWatch form

Other relevant information: \_\_\_\_\_

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.) Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid.



Iowa Department of Human Services  
**Request for Prior Authorization**  
**SELECTED BRAND NAME DRUGS**  
**Iowa Medicaid MedWatch Form**

**FAX Completed Form To**  
 1 (800) 574-2515  
**Provider Help Desk**  
 1 (877) 776-1567

Revised for submission of brand medically necessary requests for Iowa Pharmacy Program. Prescriber must have witnessed or has documentation that the manifestation of adverse event(s) is linked to generic drug. Completion of form does not automatically grant approval; incomplete forms will be returned with denial.\*\*\*

**A. PATIENT INFORMATION**

Name: \_\_\_\_\_ Sex:  F  M  
 Medicaid ID: \_\_\_\_\_ DOB: \_\_\_\_/\_\_\_\_/\_\_\_\_  
 Weight: \_\_\_\_\_ lbs Phone: (\_\_\_\_) \_\_\_\_\_  
 Has a generic been tried before?  Yes  No  
 Give date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Age at time of event: \_\_\_\_\_

**B. ADVERSE EVENT OR CONTRAINDICATION**

1.  Adverse Reaction/Treatment Failure and/or  Contraindication  
 2. Outcomes Attributed to Adverse Event: (Check all that apply.)  
 Death: \_\_\_\_\_ (month/day/year)  
 Disability  
 Life-threatening  
 Congenital Anomaly  
 Required Intervention to Prevent Permanent Impairment/Damage  
 Hospitalization – Initial or Prolonged

3. Date of Event (mo/day/yr) \_\_\_\_\_ 4. Date of This Report (mo/day/yr) \_\_\_\_\_

5. Describe Event or Problem; Relevant History & Tests

**C. SUSPECT MEDICATIONS**

1. Name (Give labeled strength & mfr/labeler, if known)  
 #1 \_\_\_\_\_  
 #2 \_\_\_\_\_

2. Dose, Frequency & Route Used  
 #1 \_\_\_\_\_  
 #2 \_\_\_\_\_

3. Therapy Dates  
 #1 \_\_\_\_\_  
 #2 \_\_\_\_\_

4. Diagnosis for Use (Indication)  
 #1 \_\_\_\_\_  
 #2 \_\_\_\_\_

5. Event Abated After Use Stopped or Dose Reduced?  
 #1  Yes  No  N/A  
 #2  Yes  No  N/A

6. Lot # (if known)  
 #1 \_\_\_\_\_  
 #2 \_\_\_\_\_

8. Event Reappeared After Reintroduction  
 #1  Yes  No  N/A  
 #2  Yes  No  N/A

9. NDC # (specify generic manufacturer)

**D. DEGREE OF CERTAINTY THAT THE ADVERSE DRUG REACTION IS DUE TO GENERIC**

\_\_\_ **Definite.** The reaction follows a reasonable temporal sequence after generic drug exposure or a toxic blood level of the generic drug has been established in body fluids or tissue. The reaction follows a recognized response to the suspected generic drug. The reaction is confirmed by improvement on withdrawing the generic drug and reappears on re-exposure. "Other than drug causes" such as other drugs or toxins or concomitant disease states that can cause similar clinical reactions are ruled out.

\_\_\_ **Probable.** The reaction follows a reasonable temporal sequence after generic drug exposure. The reaction follows a recognized response to the suspected generic drug. The reaction is confirmed by withdrawal but not by exposure to the generic drug. The reaction cannot be reasonably explained by known characteristics of the recipient's clinical state.

\_\_\_ **Possible.** The reaction follows a temporal sequence after generic drug exposure. The reaction follows a possible recognized pattern to the suspected generic drug. The reaction could be explained by the recipient's clinical state (i.e. other than the suspected generic drug).

\_\_\_ **Doubtful.** The reaction is likely to be related to factors other than the suspected generic drug.

\_\_\_ **Negative.** The findings clearly eliminate the possibility of a drug reaction caused by the generic version of the drug.

List concomitant medications being taken by patient.

**E. REPORTER CERTIFICATION**

**Signature certifies that brand is medically necessary**  
 Prescriber's Name \_\_\_\_\_  
 Signature \_\_\_\_\_ NPI # \_\_\_\_\_  
 Address: \_\_\_\_\_  
 Phone #: (\_\_\_\_) \_\_\_\_\_ - \_\_\_\_\_  
 Fax #: (\_\_\_\_) \_\_\_\_\_ - \_\_\_\_\_  
 Did the prescriber witness the ADR?  Yes  No  
 Has the ADR been previously reported to the FDA?  Yes  No

**Please FAX form to the Iowa Medicaid Pharmacy Program at 1-800-574-2515 DO NOT fax directly to the FDA**